Henlius Biotech's HLX99 Receives FDA Approval for ALS Clinical Study
CompanyDrug

Henlius Biotech’s HLX99 Receives FDA Approval for ALS Clinical Study

Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer
CompanyDrug

Henlius Biotech Doses First Patient in HLX43 Phase II Study for Esophageal Cancer

Bayer Files for Eylea 8 mg EMA Approval to Extend AMD, DME Treatment Intervals
CompanyDrug

Bayer Files for Eylea 8 mg EMA Approval to Extend AMD, DME Treatment Intervals

Bristol-Myers Squibb's Breyanzi Hits Primary Endpoint in Lymphoma Study
CompanyDrug

Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study

CSPC Pharmaceutical's SYH2039 Wins FDA Clinical Approval for Advanced Tumors
CompanyDrug

CSPC Pharmaceutical’s SYH2039 Wins FDA Clinical Approval for Advanced Tumors

Boehringer Ingelheim's Nerandomilast Hits Primary Endpoint in PPF Phase III Study
CompanyDrug

Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study

CSPC Pharmaceutical's Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma
CompanyDrug

CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025
CompanyDrug

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025

Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China
CompanyDrug

Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China

R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech
CompanyDeals

R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech

Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market
CompanyDeals

Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market

Changchun GeneScience's GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials
CompanyDrug

Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials